5.300SEK-6.85%Mkt Cap: 324.80M SEKP/E: —Last update: 2026-06-01
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical tri…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap324.80M SEK
Enterprise Value269.53M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-113.26M SEK
Revenue/Share—
Last Price5.300 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees27
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.61
PEG—
EV/EBITDA-2.54
EV/Revenue—
P/S—
P/B0.60
EPS (TTM)-1.90
EPS (Forward)-0.49
52W Range
3.86020% of range10.98
52W High10.98 SEK
52W Low3.860 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-19.36%
ROA-18.03%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.53M SEK
CapEx (TTM)307.00K SEK
FCF Margin—
FCF Yield-13.57%
Net Debt-45.81M SEK
Net Debt/EBITDA0.43
Balance Sheet
Debt/Equity0.03
Current Ratio2.69
Quick Ratio2.47
Book Value/Sh9.537 SEK
Cash/Share1.054 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 3, 2024
Analyst Consensus
Rating—
Target (Mean)16.00 SEK
Target Range16.00 SEK – 16.00 SEK
# Analysts1
Ownership
Shares Out.61.28M
Float20.69M
Insiders67.21%
Institutions13.22%
Technical
SMA 505.061 (+4.7%)
SMA 2005.606 (-5.5%)
Beta0.71
S&P 52W Chg27.70%
Avg Vol (30d)34.42K
Avg Vol (10d)26.12K
Technical Indicators
RSI (14)56.3
MACD0.1681
MACD Signal0.2052
MACD Hist.-0.0371
BB Upper6.436 SEK
BB Middle5.518 SEK
BB Lower4.600 SEK
BB Width33.28%
ATR (14)0.4780 SEK
Vol Ratio (20d)0.81x